Form 4: Evoke Pharma Director Malcolm R. Hill Reports Stock Option Grant

Director Malcolm R. Hill reports the acquisition of stock options in Evoke Pharma, Inc.

Summary

• Malcolm R. Hill, a director of Evoke Pharma Inc, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 21, 2025.
• Hill acquired stock options to purchase 1,218 shares of Evoke Pharma's common stock at an exercise price of $3.453.
• The options vest on the one-year anniversary of the grant date, contingent upon continued service to the issuer.
• Following the reported transaction, Hill beneficially owns 8,269 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a stock option grant. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.

Key Dates

Keywords

Form 4, Evoke Pharma, Stock Options, Beneficial Ownership, Director, EVOK, Malcolm R. Hill